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Objectives: The aim of this study is to analyze the quality and transferability issues reported in published peer-reviewed English-language economic evaluations based in healthcare
settings of the Central and Eastern European (CEE) and former Soviet countries.
Methods: A systematic search of economic evaluations of healthcare interventions was performed for Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Turkmenistan,
Kazakhstan, Lithuania, the former Yugoslav Republic of Macedonia, Republic of Moldova, Romania, the Russian Federation, Serbia, Slovenia, and Ukraine. The included studies were
assessed according to their characteristics, quality (using Drummond’s checklist), use of local data, and the transferability of inputs and results, if addressed.
Results: Most of the thirty-four economic evaluations identified were conducted from a healthcare or payer perspective (74 percent), with 47 percent of studies focusing on
infectious diseases. The least frequently and transparently addressed parameters were the items’ stated perspectives, relevant costs included, accurately measured costs in
appropriate units, outcomes and costs credibly valued, and uncertainties addressed. Local data were often used to assess unit costs, baseline risk, and resource usage, while
jurisdiction-specific utilities were included in only one study. Only 32 percent of relevant studies discussed the limitations of using foreign data, and 36 percent of studies discussed
the transferability of their own study results to other jurisdictions.
Conclusions: Transferability of the results is not sufficiently discussed in published economic evaluations. To simplify the transferability of studies to other jurisdictions, the following
should be comprehensively addressed: uncertainty, impact of influential parameters, and data transferability. The transparency of reporting should be improved.
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INTRODUCTION
The application of health technology assessment (HTA), a pol-
icy analysis that examines short- and long-term consequences
of the use of a health technology in decision making (1), has
significantly increased during the past years all around theworld
(2;3). At the same time, middle income countries, classified by
the World Bank as countries with a gross national income per
capita between $1,036 US and $12,475 US (4), face common
problems in establishing HTA paradigms (2). Most countries
of the Central and Eastern European (CEE) and former Soviet
Union regions are middle income countries, while many others
from the same regions (for example, the Russian Federation),
being nominally high-income markets, still possess “middle-
income characteristics” (2).
Among countries of the CEE region, Poland, the Czech
Republic, Slovakia, and Hungary have introduced HTA prin-
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ciples and so can be considered countries with an established
HTA process (5;6). The other CEE and former Soviet countries,
being in different stages of HTA implementation, frequently
incorporate some HTA elements or emerge with an idea for
HTA use in their healthcare decision making. Frequently, such
countries have no well-defined structural plan for the imple-
mentation of HTA results in their healthcare decision-making
process. Some of them express initiation for full or partial HTA
implementation, while not being able to allocate significant fi-
nancial or qualified scientific resources for substantiating policy
decisions with evidence (6;7). In many countries (e.g., Hun-
gary and Poland), HTA capacity building is a first mandatory
step for HTA implementation, followed by the development and
approval of methodological guidelines and, after having an ap-
propriately organized scientific environment, use of compulsory
HTA in policy decisions (7;8). In other countries (e.g., Slovakia)
mandating HTA evidence before pricing and reimbursement
decisions of pharmaceuticals is the first step of HTA imple-
mentation, which eventually creates the need for HTA training.
However, insufficient or low-quality HTA capacity may lead to
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speculations and corruption rather than the benefits from early
HTA implementation.
The other challenge for CEE and former Soviet coun-
tries with no central HTA agency is that when voluntary
HTA dossier submissions exist, HTA may become a commer-
cial promotional product rather than a decision-making tool.
Although pharmaceutical companies, consulting firms, or pri-
vate HTA agencies may become interested in this partic-
ular topic, the actual need for such an assessment is not
always expressed by the government. For example, while
health authorities may be equally interested in HTA for ex-
pensive medical services and procedures, most of the online
Russian-language literature on HTA studies, which was ac-
quired by means of an Internet search, is focused on pharma-
ceuticals.
Although HTA capacity is already considered to be very
limited (2), the implementation of HTA research and the crit-
ical appraisal of completed studies in CEE and former Soviet
countries with no single public HTA agencymay involve several
additional problems (6). When the appropriate training in HTA
methodologies and concepts (and more specifically economic
evaluations, being the core concept within HTA) is provided to
experts from national institutions with no formal education in
HTA or related sciences, there is no guarantee that the training
will be successful. Language barriers limit the impact of inter-
national training courses in English. Language limitations, to-
gether with quality considerations, are factors that influence the
potential transferability and generalizability of local-language
studies, which are frequently not referenced in the international
databases.
The potential solution while operating in a narrow pool of
high-quality economic studies can be generalizability or sim-
plified transferability of economic evaluations across countries
with defined similarities in healthcare systems and economic
development (6). The need for simple transferability of health
economic studies is potentially more important in countries
with limited scientific and financial resources for conducting
economic evaluations, as is the case in many countries of the
CEE and former Soviet Union (2;5;7). In this study, we an-
alyzed the scope of transferability issues that are addressed
in published peer-reviewed English-language economic eval-
uations based in healthcare settings of CEE and former So-
viet countries with a recently formed or no centralized HTA
agency. The research aim was operationalized by the following
research questions: (i) What are the background characteris-
tics of economic evaluations conducted in healthcare settings
of CEE and former Soviet countries and published in English-
language peer-review journals? (ii) What is the quality of the
retrieved studies based on Drummond’s check-list for assess-
ing economic evaluations? (iii) To what extent is the trans-
ferability of economic evaluations addressed in the retrieved
studies? (a) In what respect were local and foreign inputs used
in economic evaluations? (b) Are the transferability of the in-
puts and the results of the study frequently discussed in these
publications?
METHODS
In September 2013, a systematic search for scientific literature
on economic evaluations conducted in the selected CEE and for-
mer Soviet countries was performed (Armenia, Azerbaijan, Be-
larus, Bulgaria, Estonia, Georgia, Turkmenistan, Kazakhstan,
Lithuania, the former Yugoslav Republic ofMacedonia, Repub-
lic of Moldova, Romania, Russian Federation, Serbia, Slovenia,
andUkraine). Themethodology applied in this reviewwas based
on the recommendations of the Centre for Reviews and Dissem-
ination guidance for undertaking reviews in healthcare by the
University of York (9).
Data Search
The search, selection, and analysis of the relevant articles were
performed in a three-step procedure: initial assessment of the
title, abstract, and keywords (Step 1); a full-text assessment
of the selected references (Step 2); and analysis of the arti-
cles that fully corresponded to the inclusion criteria (Step 3).
The search terms applied to full texts of publications in the
PubMed database were as follows: “economic evaluation” +
“country” or “cost” + “country”. The extended search for key
words within abstracts (“economic evaluation” + “country”,
“cost∗” +”country”) was conducted in the Science Direct and
Scopus databases (Figure 1). The difference in search condi-
tions among databases was highlighted by the unlimited num-
ber of word combinations appearing if the term “cost∗” was
searched in PubMed.
The following exclusion criteria were applied for Step 1:
study older than 5 years (<2008) based on the publication-date
of the ISPOR task force report on transferability in 2009 (10);
abstract not available, study written in a language other than
English. The inclusion criteria for Step 1 were the following:
study includes at least one country of interest, study includes
an economic evaluation, study published as a peer-reviewed
article (abstract only, or congress report excluded) in the
English language.
Full texts of the publications were analyzed on corre-
spondence to the inclusion criteria during the second step:
study includes comparative economic evaluation, conducted in
healthcare setting of at least one country of interest, full text of
the study available. Both trial-based andmodel-based economic
evaluations were eligible for inclusion. All references included
in the second step were summarized in the dataset with the
following information: main author and year of publication,
whether it is an economic evaluation or not, inclusion of a
direct comparison of two or more technologies, countries
included in the assessment, full text availability, decision on
inclusion in the systematic review. Hard copies of potentially
relevant full-text articles were received. Authors of the articles
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Figure 1. Flowchart outlining paper selection process for the systematic review.
which corresponded to all inclusion criteria except full-text
availability were contacted. If no full text of the article was
received, the publication was withdrawn from the analysis, and
the reason for this was recorded.
Data Extraction and Reporting
The following information was summarized from the in-
cluded studies: (i) Technical characteristics of the publications:
country and affiliation of the main and corresponding author
(if differ), study sponsorship and type of sponsorship indicated.
(ii) Study characteristics: countries of analysis, clinical area,
study technology and comparators, type of analysis and meth-
ods used, perspective, application of discounting, costs assess-
ment (technology, medical, and productivity costs), outcome
measure, type of sensitivity analysis applied. (iii) Quality as-
sessment using Drummond’s check-list for assessing economic
evaluations (11). (iv) Use of local inputs for the main data cate-
gories according to Barbieri et al. (12): baseline risk, treatment
effect, health state preference values (utilities), resource usage,
unit costs (prices). (v) Addressed limitations regarding foreign
data use and transferability of the received results to other ju-
risdictions.
The articleswere assessed independently by two researchers
(O.M. and either S.K., Z.K., or J.L.S.). The results of the two
independent assessments during the third step were compared,
and any disagreements were discussed. If no consensus was
reached, a third researcher was involved in the final decision
making. The authors will provide their assessments for each of
the included article on request.
RESULTS
Of the forty-seven full-text publications, thirty-four articles
(13–46) were included in the systematic review. Fifteen of the
studies (44 percent) had a main author (and corresponding au-
thors, if different) not from a study country (Western European
countries, the United Kingdom, or the United States). An aca-
demic affiliation was the most common affiliation of the main
author (25 or 74 percent of the studies). The study’s sponsorship
was indicated in twenty-two (65 percent) publications; of these,
pharmaceutical companies sponsored five and conducted two
more studies.
Background Characteristics of Economic Evaluations
The main characteristics of the studies are described in Table 1.
The majority of the retrieved studies were conducted in the
healthcare settings of Bulgaria, the Russian Federation, Slove-
nia, Lithuania, and Ukraine. The retrieved studies also included
six cross-country studies, which additionally analyzed the ap-
plication of a technology in Croatia, Tajikistan, and Uzbekistan.
Infectious diseases were the most frequently addressed topics
in publications (16 or 47 percent of all studies), and the most
frequently funded (87 percent of infectious disease studies were
funded in comparison to 44 percent of all the other evalua-
tions). Besides pharmaceutical companies, the other sponsors of
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Table 1. Characteristics of the Included Economic Evaluations
Parameters N (%)a,b
Perspective of the study is stated c 23 (68%)
Health care, state, or health care payer 25 (74%)
Societal 5 (15%)
Provider 3 (9%)
Employer 1 (3%)
Patient 1 (3%)
Discounting applied 21 (62%)
Both costs and outcomes are discounted at 3% (%
from model studies)
10 (43%)
Both costs and outcomes are discounted at 5% (%
from model studies)
4 (17%)
Unequal discounting for costs and effects (% from
model studies)
4 (17%)
Productivity costs included outcomes used 5 (15%)
Quality adjusted life yearsd 18 (53%)
Life-years gained 13 (38%)
N of cases/deaths averted 6 (18%)
Disability adjusted life years 5 (15%)
Sensitivity assessede 27 (79%)
Probabilistic sensitivity analysis reported (% from
model studies)
11 (48%)
Only univariate analysis 11 (32%)
Only univariate with multivariate analyses 4 (12%)
Bootstrap 1 (3%)
aThirty-four articles in total.
bRounding is applied.
cNumber of studies used several perspectives.
dOne study assessed quality of life using WHOQOL-BREF instrument.
eTwo studies indicated that sensitivity analysis was applied, but did not report the results.
studies on infectious diseases were international organizations,
European and the U.S. grant committees, Ministries of Health
or universities. In studies considering chronic diseases, different
cardiologic interventions and diabetes medicines were the most
frequently addressed. Medicines were the most frequently re-
searched interventions, among which vaccines had a significant
share. Healthcare, governmental, or healthcare payer perspec-
tives were predominant in the analyzed publications. Models
were applied in two-third of the studies (Markov model was fre-
quently used). Cost-utility analysis, with quality-adjusted life-
years (QALY) at the effect side, was applied in more than half
of the evaluations.
Quality of Economic Evaluations
The summary of the assessment of the articles are presented in
Table 2. Using Drummond’s check-list for assessing economic
evaluations (including considerations of internal and external
validity of the study, such as methodology applied and health-
care setting) it was observed that the following criteria were
ranked as “no” and “unclear” in more than 30 percent of stud-
ies: perspective stated, all relevant costs included, costs mea-
sured accurately in appropriate units, outcomes and costs val-
ued credibly, and uncertainty addressed. Appraisal criteria such
as comprehensive description of alternatives given, all relevant
outcomes included, outcomes measured accurately in appro-
priate units, outcomes and costs adjusted for different times,
incremental analysis performed, and conclusions justified by
the evidence presented, were ranked as “yes” more than other
Drummond criteria. Insufficient information on costs compo-
nents and assessment methods frequently made it impossible to
evaluate the quality of these data.
Address of Transferability in Economic Evaluations
In ten of the twenty-three studies, the use of a country-adapted
model was clearly stated. The frequencies on other transferabil-
ity issues ranking are presented in Table 2. Unit costs were most
frequently based on local data; there was only one study which
did not apply local unit costs. The baseline risk and resource
usage were also frequently assessed using local inputs, while
the utility parameters were clearly identified as local in only
one study.
Limitations of the results regarding the use of foreign data
were discussed at least partially in eight studies, and twelve
studies at least partially discussed the transferability of study
results to other jurisdictions. Several studies briefly discussed
the generalizability of the results or individual parameters (such
as baseline risk, prevalence), while the studies of Berkhof et al.
(15) and Winetsky et al. (46) generalized the received results
to the other countries of the region (or conducted a simple
transferability assessment).
DISCUSSION
The results of this systematic review of economic evaluations
conducted in CEE and former Soviet countries allowed us to
conclude a low transparency of data reporting in the analyzed
publications as well as insufficient consideration of inputs and
results transferability in these studies.
Background Characteristics of Economic Evaluations
We did not observe any proportional difference in the number of
available English-language peer-review publications referenced
in the international databases based on the country’s size or
level of HTA development. While the topic of the study may
be sponsorship-driven, the number of publications submitted to
international journals may depend on the publication activity of
the local research teams. This conclusion is supported by the
observation that, in the countries with a relatively high number
of publications (such as Bulgaria and Lithuania), the articles
are frequently published by the same teams. Additionally, we
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Table 2. Quality and Transferability of the Included Economic Evaluationsa
Parameters Yesb Partiallyb Nob Unclearb
Comprehensive description of alternatives given 27 (79%) 0 6 (18%) 1 (3%)
Effectiveness is established 22 (65%) 3 (9%) 2 (6%) 7 (21%)
All relevant costs included 18 (53%) 0 6 (18%) 10 (29%)
All relevant outcomes included 29 (85%) 2 (6%) 3 (9%) 0
Costs measured accurately in appropriate units 17 (50%) 0 1 (3%) 16 (47%)
Outcomes measured accurately in appropriate units 26 (76%) 5 (15%) 1 (3%) 2 (6%)
Outcomes and costs valued credibly 13 (38%) 5 (15%) 3 (9%) 13 (38%)
Incremental analysis performed (33 applicable)c 27 (82%) 1 (3%) 4 (12%) 1 (3%)
Uncertainty addressed 12 (35%) 11 (32%) 9 (26%) 2 (6%)
Results include issues of purchasers concern 18 (53%) 7 (21%) 5 (15%) 4 (12%)
Conclusions justified by the evidence presented 25 (74%) 4 (12%) 5 (15%) 0
Results can be applied to the local population 31 (91%) 1 (3%) 1 (3)% 1 (3%)
Unit costs retrieved from local data 28 (82%) 4 (12%) 1 (3%) 1 (3%)
Resource utilization retrieved from local data 23 (68%) 2 (6%) 1 (3%) 8 (24%)
Utility parameters retrieved from local data (19 applicable)c 1 (5%) 0 18 (95%) 0
Baseline risk received from local data (32 applicable)c 23 (72%) 2 (6%) 7 (22%) 0
Treatment effect received from local data 15 (44%) 2 (6%) 16 (47%) 1 (3%)
Transferability of study to other jurisdiction was discussed 4 (12%) 8 (24%) 22 (65%) –
Limitations of the results regarding foreign data used (25 applicable)c 4 (16%) 4 (16%)a 17 (68%) –
aThirty-four articles in total.
bRounding is applied.
cPercentage is indicated from applicable.
observed a trend for sponsored studies and for studies conducted
under international co-authorship (either the first author or the
corresponding author is not affiliated with the study country)
to be of higher quality as assessed by Drummond’s criteria.
While it could be noticed that studies on some technologies
were of better quality (e.g., vaccines), we believe that the main
factor influencing study quality is the authors’ affiliation and
source of sponsorship. A similar observation of higher quality
of economic studies conducted by international rather than local
teams was made in a systematic review of economic studies in
Vietnam (47).
While it appears that medical interventions other than phar-
maceuticals as well as studies on chronic conditions may be of
higher interest for the decision makers, the analyzed publica-
tions tend to present more analyses related to drug treatment,
especially vaccination, and focus more on infectious diseases
than on chronic diseases.
Despite the fact that most guidelines on economic evalu-
ations recommend using the societal perspective (48), its ap-
plication in CEE and former Soviet countries is limited. Only
a few studies used a limited or not purely societal perspec-
tive as defined by the ISPOR task force report (49). Data
availability and decision-makers’ acceptance are the key fac-
tors in defining the perspective of the study (10) which, in
the studied countries, majorly concern healthcare or third-party
payers.
Quality of Economic Evaluations
Insufficient quality of economic evaluations is the first knock-
out criterion in assessment of studies’ transferability (50) and
lack of transparency in the reporting of economic evaluations is
the major concern of decision makers around the world (3;51).
At the same time, we observed a significant indistinctness in
reporting the methodology of economic evaluations conducted
in healthcare settings of CEE and former Soviet countries. This
reporting approach may improve by using standardized instru-
ments, such as the CHEERS statement (52).
Absence of a clearly stated perspective of the study causes
difficulties in the assessment of both the credibility of the study
and its application in the decision making context. The de-
scription of the economic model used and its authorship was
frequently lacking. Together with missing reporting on internal
and external (between-model) validation (53), this may create
difficulties for the transferability of study results.
While costs choice fully depends on the perspective of the
analysis, their values and measurements should be transpar-
ent, appropriately documented and available for readers (49).
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However, incompleteness of data, the sample size required to
estimate population-representative costs and effects, data het-
erogeneity, and generalizability of trials’ results are required
(53), but rarely reported, in the trial-based economic evalu-
ations conducted in healthcare settings of CEE and former
Soviet countries. At the same time in countries with high
data uncertainty, comprehensive probabilistic sensitivity assess-
ment in modeled studies may improve the perceived quality
(or reliability) of a study and thus the use of economic evalua-
tions in the decision-making process (3).
Consideration of Transferability of Economic Evaluations
While economic evaluations conducted in CEE and former So-
viet countries typically apply local costs, baseline risk and re-
source usage measurement, the effectiveness and utilities are
frequently extrapolated from other countries or multinational
studies. This observation corresponds to the conclusions of
other authors defining baseline risk, unit costs, and resource
use as parameters of low transferability (12;54).
Many guidelines recommend using utility values from the
jurisdiction of interest (10). The evidence suggests that utili-
ties may vary between countries (55). Meanwhile, taking into
account the data constraints, the decision makers from CEE
and former Soviet countries may review generalizability of
outcomes while addressing its uncertainty using statistical ap-
proaches.
Moreover, we observed that the limitations of foreign data
use, as well as the possibility of transferring the study to other
jurisdictions, are rarely described in the analyzed publications.
Clear presentation of these parameters together with defining
major impact factors on the results of economic evaluations and
addressing data uncertainty will improve the transferability of
studies.
Policy and Future Research Considerations
Because of the limited HTA capacity, geographic transferability
is an important alternative to conducting country-specific eco-
nomic studies (56). Meanwhile, CEE and former Soviet coun-
tries require an adapted approach to addressing the use and
transferability of economic evaluations in healthcare decision
making. Because of the information (data and knowledge) con-
straints, this approachmay not always correspond to the interna-
tional guidelines on economic evaluations or practices used in
HTA-experienced countries. As such, healthcare or third-party
payer perspectives may be preferable to a societal one, and the
generalizability of utilities may be considered to be appropri-
ate, while local data should be used for baseline risk, unit costs,
and resources consumption. The decision-makers’ preferences
in these countries should be analyzed to understand the im-
portance and relevance of studies’ methodology and possible
impact of economic evaluations on a decision-making process.
Limitations
This study is limited due to the use of the following study
selection criteria: (i) English-language publications only, (ii)
studies published from 2008 onward, (iii) articles with full-text
availability. Search limitations could result in noninclusion of
some relevant studies. Drummond’s criteria were used to assess
the quality of the economic evaluations. This instrument is a
general questionnaire and does not provide a total scoring of
the quality of the assessed papers, leaving the conclusion on
each article to the subjective judgment of the people assessing
it. The limited number of selected articles causes that the study
does not have the statistical power to provide an assessment of
relationships between different characteristics.
CONCLUSION
Transferability of economic evaluations, conducted in health-
care settings of CEE and former Soviet countries is limited by
a low number of English language peer-reviewed studies es-
pecially in chronic diseases, underreporting of methodology in
publications, and limited discussion on inputs and results trans-
ferability. To improve the transferability of published studies to
other jurisdictions, uncertainty, the impact of influential param-
eters, and data transferability should be comprehensively ad-
dressed when reporting studies. Additionally, the transparency
of study reporting, especially study perspective, model details,
and costing methodology, should be improved significantly.
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